GlassScriptPhysician profile
Bacharanianda C Muthappa
NPI 1396835427
$2,764.04
in general payments reported to CMS, 2019-2025
30 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $249 · 2021: $454 · 2022: $387 · 2023: $501 · 2024: $509 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $535.18 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $495.60 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $241.12 | 2023-2025 | Otezla, Repatha, Repatha |
| Mylan Specialty L.P. | $159.49 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $157.47 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Pfizer INC. | $130.97 | 2019-2024 | |
| Puma Biotechnology, INC. | $125.00 | 2021 | |
| Novo Nordisk INC | $124.91 | 2019-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $123.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.47 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $69.58 | 2023-2025 | Quviviq, Quviviq |
| Abbvie INC. | $52.32 | 2021-2024 | |
| Philips North America LLC | $45.70 | 2024 | (Ck7) Extended Holter |
| Dexcom, INC. | $41.56 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $40.46 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $38.55 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $31.31 | 2023-2024 | Loreev Xr, Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.97 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $24.09 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.50 | 2024 | Voquezna |
| Astellas Pharma US INC | $22.13 | 2023 | Myrbetriq |
| Leadiant Biosciences, INC. | $20.63 | 2025 | Cystaran |
| Shield Therapeutics INC | $20.09 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.70 | 2023 | |
| Eisai INC. | $16.45 | 2020 | |
| Aimmune Therapeutics, INC. | $15.20 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.66 | 2023 | Xarelto |
| Exact Sciences Corporation | $13.95 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $11.31 | 2019 | |
| Corium, LLC | $10.90 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bacharanianda Muthappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.